Immunovant, Inc. (IMVT): Price and Financial Metrics
IMVT Price/Volume Stats
| Current price | $25.86 | 52-week high | $45.58 |
| Prev. close | $25.66 | 52-week low | $24.61 |
| Day low | $25.25 | Volume | 3,237,200 |
| Day high | $26.27 | Avg. volume | 1,070,242 |
| 50-day MA | $28.56 | Dividend yield | N/A |
| 200-day MA | $29.09 | Market Cap | 3.80B |
IMVT Stock Price Chart Interactive Chart >
Immunovant, Inc. (IMVT) Company Bio
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as has completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
IMVT Price Returns
| 1-mo | -2.56% |
| 3-mo | -11.53% |
| 6-mo | -5.52% |
| 1-year | -37.66% |
| 3-year | 231.96% |
| 5-year | 63.77% |
| YTD | -38.62% |
| 2023 | 137.35% |
| 2022 | 108.33% |
| 2021 | -81.55% |
| 2020 | 191.05% |
| 2019 | N/A |
Loading social stream, please wait...